Marc Martinez Llordella
Founder Quell Therapeutics
Dr. Marc Martinez Llordella is the Co-Founder and Vice President of Biology at Quell Therapeutics, where he leads the company’s pioneering work in developing engineered regulatory T cell (Treg) therapies for immune-related diseases. With over 15 years of experience in immunology and cell therapy, Marc has been instrumental in advancing Quell’s CAR-Treg platform and Foxp3 phenotype lock technology toward clinical translation.
Alongside his leadership at Quell, Marc serves as a Visiting Senior Lecturer at King’s College London. He earned his Ph.D. in Biomedicine from the University of Barcelona, with postdoctoral research at the University of California, San Francisco.
Seminars
A closed door discussion uniting top C-level executives from biotech and senior executives from pharma to discuss the most pressing challenges and advancements shaping the CAR-TCR field in Europe. This year’s Think Tank explores Tregs in autoimmune disease to understand how they can be leveraged as therapies and their significance when other effector cell therapies are used.
Invite Only
